Noven Pharmaceuticals, Inc. (NOVN) surprised on estimates by 60% in the third quarter as revenue rose 18%. The company has surprised on estimates 3 out of the last 4 quarters by an average of 36.67%. NOVN is trading at 14.5x forward earnings.

Company Description

Noven Pharmaceuticals manufactures specialty drugs in three areas, transdermal drug delivery, the Novogyne joint venture with Novartis, and Noven Therapeutics. Noven’s transdermal products include Vivell-Dot, the most prescribed estrogen patch in the U.S. and Daytrana, the only patch approved for the treatment of ADHD.

Noven Beat Wall Street Estimates by 60% in the Third Quarter

On Nov 6, Noven announced third-quarter results that surprised on analysts’ estimates by 9 cents per share. Net income was $5.2 million, or 21 cents a share. Excluding items and tax effects, net income was $5.9 million, or 24 cents, compared to $7.6 million, or 30 cents per share, in the third quarter of 2007. Analysts expected 15 cents.

Revenue rose 18% to $25.7 million from a year ago due to the acquisition of Noven Therapeutics on Aug 14, 2007 and increased license and contract revenues. The company also launched Stavzor in August 2008 after the drug got FDA approval in July.

Consensus Estimates Rise for 2008

Analysts are upbeat about the remainder of 2008 as fourth quarter estimates are up 9 cents to 22 cents in the last 60 days. Full year estimates moved 28.3% higher to 77 cents from 60 cents in the last 2 months.

The story is less clear for 2009 as consensus estimates are currently trending 1.77% under 2008 estimates. Estimates are up 4 cents to 76 cents in the last 60 days. Analysts expect 5-year earnings growth of 20%.

Value Fundamentals

Noven Pharmaceuticals is a Zacks #1 Rank (strong buy) stock. It is trading at 14.5x forward earnings. The company’s price-to-book is 1.83. Noven has a solid 5-year return on equity (ROE) of 11.08%.

Content Courtesy: Zacks Investment Research

#1 Ranked Stocks Highlight Archive
To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions.

1. (NWE) NorthWestern Corporation – Beat Wall Street Estimates for the Third Quarter by 20.69%NorthWestern Corporation (NWE) raised 2008 guidance in October as electricity rates have risen compared to...
2. (AVCT) Avocent Corporation – reported third-quarter earnings that beat Wall Street estimates by 81%Avocent Corporation (AVCT) recently reaffirmed its fourth quarter guidance after posting record third quarter revenue....
3. (SYKE) SYKES Enterprises – reported third-quarter 2008 earnings that beat Wall Street estimates by 67.86%SYKES Enterprises Inc. (SYKE) finds itself in an enviable position during this credit crisis with...
4. (CRI) Carter’s, Inc – third-quarter 2008 earnings that beat Wall Street estimates by 25%Carter’s, Inc. (CRI) is bucking the retail doom and gloom as it intends to open...
5. (HT) Warner Chilcott – Beat Wall Street Estimates for the Third Quarter by 18.18%Warner Chilcott Limited (WCRX) beat Wall Street estimates in the third-quarter by 18.18% as its...
6. (HS) – Healthspring – Beat Wall Street Estimates for the Second Quarter by 60%Healthspring is weathering the Wall Street financial storm as revenues rose 47% in the second...

Search Posts by Tag: Noven Pharmaceuticals Inc. | NOVN | VitalStocks | Drug Delivery | Healthcare

RSS Feeds by Tag: Noven Pharmaceuticals Inc. | NOVN | VitalStocks | Drug Delivery | Healthcare |

Other Posts by: Shawn | RSS Feed for this author